MTOR and myeloid sarcoma: In humans, clinical trials with mTOR inhibitors (rapamycin/sirolimus, temsirolimus, metformin) aimed to assess potential beneficial effects for patients with MS, both clinical and mechanistic, the latter by examining different cell types and cytokines implicated in MS pathophysiology.